1. A 61-year-old man on ticagrelor 90 mg twice daily and aspirin 81 mg for DAPT (dual antiplatelet therapy) following drug-eluting stent placement 8 months ago is found on elective evaluation to have severe three-vessel coronary artery disease not amenable to repeat PCI (percutaneous coronary intervention). The cardiac surgery team recommends coronary artery bypass grafting (CABG). The team debates the optimal timing of surgery relative to ticagrelor discontinuation and whether cangrelor bridging is needed in the interval. Which of the following best describes the evidence-based perioperative management of ticagrelor in this patient?

• A) Ticagrelor should be held for 7 days before CABG because its reversible binding mechanism requires full platelet turnover before surgical hemostasis is reliable; cangrelor bridging at 4 mcg/kg/min is recommended throughout the 7-day hold to prevent stent thrombosis during the bridging interval.
• B) Ticagrelor should be held for 5 days before CABG; because ticagrelor's binding is reversible and platelet function recovers progressively as plasma concentrations decline, 5 days is sufficient to restore adequate surgical hemostasis in most patients; cangrelor bridging is not a standard recommendation during elective CABG preparation for ticagrelor because the reversible offset is predictable and IV bridging introduces complexity without established benefit in this setting.
• C) Ticagrelor can be held for only 3 days before CABG because its reversible binding produces a faster platelet function recovery than irreversible thienopyridines; the 3-day hold is formally supported by current cardiothoracic surgery guidelines as sufficient to restore surgical-level hemostasis.
• D) Ticagrelor requires a 10-day hold before CABG because residual ticagrelor bound to red blood cell membranes maintains pharmacologically active plasma concentrations for up to 10 days after the last dose; platelet function testing is mandatory before proceeding to avoid surgical bleeding complications.
• E) Ticagrelor should be continued until the day before CABG because its reversible binding allows platelet function to normalize within 6 hours of the final dose; the very short functional offset eliminates the need for any pre-operative hold period and allows surgery to be scheduled without delay.

2. A 58-year-old man with a recent NSTEMI (non-ST-elevation myocardial infarction) and drug-eluting stent placement is discharged on clopidogrel 75 mg daily, aspirin 81 mg daily, and omeprazole 20 mg daily for gastrointestinal protection. He is a CYP2C19 extensive metabolizer. Six weeks later his cardiologist reviews a platelet function study showing higher-than-expected residual platelet aggregability. The cardiologist suspects a pharmacokinetic drug interaction. Which of the following best explains the mechanism of this interaction and identifies the preferred alternative?

• A) Omeprazole inhibits intestinal P-glycoprotein (P-gp), reducing clopidogrel absorption from the gut lumen; the reduced bioavailability of the clopidogrel prodrug limits the substrate available for hepatic bioactivation and decreases active thiol metabolite exposure; switching to a PPI that does not inhibit P-gp resolves the interaction.
• B) Omeprazole induces CYP3A4 through pregnane X receptor (PXR) activation, accelerating conversion of the clopidogrel active thiol to an inactive sulfoxide metabolite before it can bind P2Y12; switching to pantoprazole resolves the interaction because pantoprazole does not induce CYP3A4.
• C) Omeprazole raises gastric pH, converting clopidogrel to an inactive carboxylic acid hydrolysis product in the stomach before absorption; the resulting reduction in intact prodrug reaching the portal circulation reduces active thiol generation; enteric-coated clopidogrel formulations circumvent this interaction.
• D) Omeprazole and esomeprazole are significant CYP2C19 substrates and inhibitors; by competing for and inhibiting CYP2C19, they reduce hepatic bioactivation of clopidogrel to its active thiol metabolite, decreasing platelet inhibition; pantoprazole has minimal CYP2C19 inhibitory activity and is the preferred PPI when clopidogrel is co-prescribed.
• E) Omeprazole directly binds the clopidogrel active thiol metabolite in plasma through a reactive sulfhydryl group, forming an inactive mixed disulfide complex before the metabolite can reach platelet P2Y12 receptors; the interaction is concentration-dependent and is avoided by separating clopidogrel and omeprazole dosing by at least 4 hours.

3. A 66-year-old woman undergoes PCI (percutaneous coronary intervention) for STEMI (ST-elevation myocardial infarction) and receives unfractionated heparin and tirofiban during the procedure. Four hours after starting tirofiban her platelet count has fallen from 195,000/mcL to 22,000/mcL. She has no prior exposure to heparin or any GP IIb/IIIa inhibitor. The team considers two diagnoses: GP IIb/IIIa inhibitor-induced thrombocytopenia and heparin-induced thrombocytopenia (HIT). Which of the following features most reliably distinguishes GP IIb/IIIa inhibitor-induced thrombocytopenia from HIT in this patient, and correctly characterizes the underlying immunological mechanism of the GP IIb/IIIa inhibitor reaction?

• A) The onset of severe thrombocytopenia within 4 hours of first drug exposure is characteristic of GP IIb/IIIa inhibitor-induced thrombocytopenia, mediated by naturally occurring antibodies against ligand-induced binding site (LIBS) neoepitopes that are present without prior sensitization; HIT typically presents as a fall in platelet count beginning 5 to 10 days after heparin initiation in previously unexposed patients, because HIT requires immune sensitization and antibody formation against platelet factor 4 (PF4)-heparin complexes — a process that takes days; the acute 4-hour onset in this patient is therefore more consistent with GP IIb/IIIa inhibitor thrombocytopenia than with HIT.
• B) The concurrent use of both heparin and tirofiban makes it impossible to clinically distinguish the two causes; the only reliable differentiating test is a serotonin release assay (SRA) performed immediately at the time of thrombocytopenia onset, which is positive in HIT and negative in GP IIb/IIIa inhibitor thrombocytopenia; until SRA results are available, both drugs must be continued to avoid a thrombotic gap.
• C) GP IIb/IIIa inhibitor thrombocytopenia only occurs in patients with prior exposure to the same agent, because the responsible antibodies require an initial sensitizing dose before reaching titers sufficient for clinical thrombocytopenia; the absence of prior tirofiban exposure in this patient effectively excludes GP IIb/IIIa inhibitor thrombocytopenia and makes HIT the more likely diagnosis.
• D) Both GP IIb/IIIa inhibitor thrombocytopenia and HIT characteristically present within 4 to 6 hours of drug initiation regardless of prior exposure; the distinguishing feature is platelet count nadir: nadirs below 20,000/mcL are pathognomonic for HIT while GP IIb/IIIa inhibitor thrombocytopenia rarely produces counts below 50,000/mcL.
• E) HIT is diagnosed by thrombocytopenia onset within the first 24 hours of heparin exposure in all patients regardless of prior exposure history; GP IIb/IIIa inhibitor thrombocytopenia occurs only after 5 to 10 days of continuous infusion as drug accumulates to concentrations that expose LIBS epitopes; the 4-hour onset therefore excludes GP IIb/IIIa inhibitor thrombocytopenia and is consistent with immediate-onset HIT.

4. A 68-year-old woman is admitted following a non-cardioembolic ischemic stroke confirmed on MRI. Cardiac workup including prolonged rhythm monitoring excludes atrial fibrillation. Her cardiologist and neurologist discuss secondary prevention antiplatelet options. The neurologist recommends extended-release dipyridamole plus aspirin (ER-DP/ASA) and explains to the team why this combination provides superior secondary stroke prevention compared to aspirin alone, and how it compares to clopidogrel monotherapy for this indication. Which of the following most accurately characterizes the pharmacological rationale for the ER-DP/ASA combination and its current guideline status for secondary stroke prevention?

• A) ER-DP/ASA is preferred over clopidogrel for secondary stroke prevention because dipyridamole inhibits P2Y12 through a non-competitive allosteric mechanism identical to ticagrelor, while aspirin adds COX-1 inhibition; the combination of P2Y12 and COX-1 blockade in a single formulation provides superior dual antiplatelet coverage compared to clopidogrel alone.
• B) ER-DP/ASA produces superior secondary stroke prevention because dipyridamole inhibits platelet P2Y1 receptors, blocking the transient calcium-mediated activation signal that aspirin cannot suppress; the combination eliminates both the TXA2 and the ADP-calcium activation pathways simultaneously, providing more complete platelet inhibition than clopidogrel which only blocks P2Y12.
• C) ER-DP/ASA combines aspirin's irreversible COX-1 inhibition (blocking TXA2 synthesis) with dipyridamole's PDE5 inhibition (raising platelet cGMP) and adenosine reuptake inhibition (raising platelet cAMP via A2A receptors); this mechanistically complementary combination has demonstrated superiority over aspirin alone and equivalence to clopidogrel monotherapy for secondary prevention of non-cardioembolic ischemic stroke or TIA in clinical trials, and both ER-DP/ASA and clopidogrel are guideline-recommended options for this indication.
• D) ER-DP/ASA is guideline-preferred over clopidogrel for secondary stroke prevention because the CAPRIE trial demonstrated that the ER-DP/ASA combination reduced recurrent stroke, MI, and vascular death significantly more than clopidogrel 75 mg daily; clopidogrel is reserved for patients who are intolerant of aspirin or dipyridamole.
• E) Dipyridamole in the ER-DP/ASA combination acts primarily as a pharmacokinetic enhancer that increases aspirin bioavailability by inhibiting intestinal P-glycoprotein; the improved aspirin exposure produces more complete platelet COX-1 inhibition than aspirin alone; dipyridamole has no independent antiplatelet mechanism at the doses used in the combination product.

5. A 55-year-old man without prior stroke or TIA (transient ischemic attack) underwent drug-eluting stent placement 6 weeks ago for NSTEMI (non-ST-elevation myocardial infarction) and was discharged on clopidogrel 75 mg daily and aspirin 81 mg. He now presents with angiographically confirmed sub-acute stent thrombosis. Pharmacogenomic testing reveals he carries two CYP2C19 loss-of-function alleles (CYP2C19*2/*2), classifying him as a poor metabolizer. He weighs 82 kg and has no renal impairment. Which of the following represents the most pharmacologically appropriate adjustment to his P2Y12 inhibitor regimen and correctly explains why the identified alternative is preferred over maintaining clopidogrel?

• A) Increase clopidogrel to 150 mg daily; doubling the prodrug dose compensates for reduced CYP2C19 bioactivation in poor metabolizers by providing more substrate for the residual enzymatic activity of the dysfunctional CYP2C19*2 allele, restoring active thiol exposure to levels equivalent to standard dosing in extensive metabolizers.
• B) Switch to vorapaxar 2.5 mg daily in addition to clopidogrel; vorapaxar's PAR-1 antagonism operates entirely independently of the CYP2C19 pathway and provides supplemental platelet inhibition through the thrombin receptor pathway without requiring any CYP-dependent bioactivation.
• C) Switch to aspirin 325 mg daily as the sole antiplatelet agent; the higher aspirin dose achieves more complete COX-2 inhibition in nucleated inflammatory cells, compensating for the loss of P2Y12 inhibition in a poor metabolizer and providing equivalent secondary prevention to clopidogrel in this genetic subgroup.
• D) Switch to dipyridamole ER plus aspirin; dipyridamole's PDE5 inhibition and adenosine reuptake inhibition are CYP2C19-independent and provide P2Y12-equivalent platelet inhibition that is unaffected by metabolizer status; this combination is the guideline-preferred alternative to clopidogrel for post-PCI antiplatelet therapy in poor metabolizers.
• E) Switch to prasugrel 10 mg daily or ticagrelor 90 mg twice daily; both agents overcome the CYP2C19 poor metabolizer limitation — prasugrel requires only a single CYP step (substantially less CYP2C19-dependent than clopidogrel's two steps) and ticagrelor is a direct-acting agent requiring no CYP bioactivation — producing reliable, potent P2Y12 inhibition regardless of CYP2C19 genotype in a patient who has already demonstrated the clinical consequence of inadequate clopidogrel bioactivation.

6. A 70-year-old man with stage 4 chronic kidney disease (CKD; estimated CrCl 18 mL/min, not yet on dialysis) presents with an NSTEMI (non-ST-elevation myocardial infarction) and undergoes PCI (percutaneous coronary intervention) with drug-eluting stent placement. The interventional team must select both a P2Y12 inhibitor for post-PCI DAPT (dual antiplatelet therapy) and, if needed, a GP IIb/IIIa inhibitor for procedural support given a moderately large thrombus burden identified at the time of intervention. Which of the following correctly characterizes the drug selection principles for both antiplatelet categories in this patient with advanced CKD?

• A) Prasugrel is preferred over clopidogrel in CKD because reduced renal clearance of clopidogrel's active thiol metabolite paradoxically increases its platelet inhibitory effect in advanced CKD, producing excessive bleeding risk; prasugrel's renal-independent bioactivation makes its pharmacokinetics more predictable; abciximab requires dose reduction at CrCl below 30 mL/min.
• B) Clopidogrel is preferred over prasugrel for P2Y12 inhibition in patients with CKD and ACS (acute coronary syndrome) because prasugrel carries greater bleeding risk (established in TRITON-TIMI 38) and the excess bleeding risk is amplified in CKD where platelet dysfunction from uremia already increases hemorrhagic risk; for GP IIb/IIIa support, abciximab does not require renal dose adjustment and is acceptable, while eptifibatide infusion rate must be halved at CrCl 10–50 mL/min and eptifibatide is contraindicated in dialysis patients.
• C) Ticagrelor is the only P2Y12 inhibitor that requires dose reduction in advanced CKD; the recommended ticagrelor dose is 60 mg twice daily (the secondary prevention dose) in patients with CrCl below 30 mL/min to reduce exposure of the active metabolite AR-C124910XX, which accumulates renally; clopidogrel and prasugrel can be used at standard doses without adjustment in any degree of CKD.
• D) All three P2Y12 inhibitors are contraindicated in patients with CrCl below 30 mL/min due to accumulation of active metabolites; dialysis-dependent patients with ACS requiring PCI should receive aspirin monotherapy until renal function improves sufficiently to allow P2Y12 inhibitor use.
• E) For GP IIb/IIIa support in this patient, tirofiban is the preferred agent because it does not require renal dose adjustment at any level of CKD; eptifibatide is the agent most affected by renal impairment and should be avoided entirely at CrCl below 50 mL/min; prasugrel is preferred over clopidogrel for post-PCI DAPT in CKD because its more potent platelet inhibition compensates for the blunted platelet response seen in uremia.

7. A cardiologist considers adding vorapaxar 2.5 mg daily to the regimen of a 64-year-old man with a myocardial infarction three years ago who is maintained on aspirin 81 mg daily. The patient has no history of stroke or TIA (transient ischemic attack). A resident asks the attending to explain, at the mechanistic level, what pharmacological gap vorapaxar fills that aspirin does not address, and why combining the two agents provides additive rather than redundant antithrombotic benefit. Which of the following correctly identifies the mechanistic basis for the complementary antithrombotic effects of aspirin and vorapaxar?

• A) Aspirin and vorapaxar act redundantly rather than complementarily, because both ultimately prevent GP IIb/IIIa activation — aspirin by reducing TXA2-mediated TP receptor signaling and vorapaxar by blocking PAR-1-mediated Gq activation, both of which converge on the same inside-out signaling cascade; adding vorapaxar to aspirin therefore doubles inhibition of the same downstream pathway.
• B) Vorapaxar fills the gap left by aspirin's inability to inhibit ADP-mediated platelet activation; aspirin targets TXA2 synthesis via COX-1 but has no effect on ADP release from dense granules or P2Y12 signaling; vorapaxar blocks ADP-driven Gi-mediated cAMP reduction through PAR-1's allosteric interaction with P2Y12, providing the complementary ADP-pathway coverage that aspirin lacks.
• C) Vorapaxar's value over aspirin lies in its ability to inhibit platelet adhesion to subendothelial collagen via GP VI; aspirin reduces platelet activation amplification signals (TXA2) but cannot prevent the initial GP VI-collagen interaction that triggers the platelet activation cascade; vorapaxar's PAR-1 antagonism coincidentally blocks the GP VI signaling pathway through a shared Syk kinase intermediate.
• D) Aspirin inhibits TXA2-mediated platelet activation by irreversibly acetylating COX-1, but has no effect on thrombin-mediated platelet activation through PAR-1 (protease-activated receptor-1); vorapaxar antagonizes PAR-1, blocking the potent, thrombin-driven platelet activation pathway that aspirin leaves unaddressed; because TXA2 and thrombin activate platelets through distinct receptor-signaling axes, the combination provides genuinely additive inhibition at two independent nodes of the activation cascade.
• E) Vorapaxar complements aspirin by inhibiting the vascular endothelial PAR-1 receptor rather than the platelet PAR-1 receptor; aspirin reduces platelet TXA2 production while vorapaxar reduces endothelial PAR-1-mediated tissue factor expression, producing additive antithrombotic benefit through parallel but anatomically distinct pathways.

8. A hematologist is consulted on a 38-year-old woman with known Glanzmann thrombasthenia (absent GP IIb/IIIa, integrin alphaIIb beta3) who has just survived a myocardial infarction and requires secondary prevention antiplatelet therapy. The cardiologist asks which antiplatelet agents would be pharmacologically effective in this patient. The hematologist explains that the choice of agent must account for the missing receptor's position in the platelet activation cascade. Which of the following most accurately identifies which antiplatelet drug classes would produce meaningful inhibition of residual platelet function in a patient with Glanzmann thrombasthenia, and explains the reasoning?

• A) In Glanzmann thrombasthenia, GP IIb/IIIa is absent, meaning fibrinogen-mediated platelet crosslinking cannot occur regardless of the activation state of the platelets; agents acting upstream of GP IIb/IIIa — including aspirin (COX-1 inhibition, reducing TXA2), P2Y12 inhibitors (reducing ADP-sustained activation), PAR-1 antagonists (blocking thrombin-mediated activation), and GP IIb/IIIa inhibitors (targeting the absent receptor) — cannot further inhibit platelet aggregation because the aggregation-mediating receptor is already absent; standard antiplatelet drugs provide no additional aggregation inhibition in Glanzmann thrombasthenia, and platelet transfusion or recombinant activated factor VII (rFVIIa) are the hemostatic management tools rather than antiplatelet therapy.
• B) Aspirin remains fully effective in Glanzmann thrombasthenia because COX-1 is intact and TXA2 synthesis still occurs; TXA2 can still produce platelet shape change and secretion (degranulation) even without GP IIb/IIIa, and reducing TXA2 reduces these upstream activation events; aspirin therefore provides meaningful secondary prevention benefit independent of the absent GP IIb/IIIa.
• C) P2Y12 inhibitors are effective in Glanzmann thrombasthenia because P2Y12 signaling controls a parallel aggregation pathway through integrin alpha-2 beta-1 (GP Ia/IIa) that is upregulated in the absence of GP IIb/IIIa to compensate for lost fibrinogen-mediated aggregation; blocking P2Y12 reduces this compensatory alpha-2 beta-1-mediated aggregation.
• D) Vorapaxar is the preferred antiplatelet agent in Glanzmann thrombasthenia because thrombin-mediated PAR-1 activation triggers a GP IIb/IIIa-independent aggregation pathway through PAR-1's direct interaction with von Willebrand factor multimers; vorapaxar blocks this alternative aggregation mechanism that is upregulated when GP IIb/IIIa is absent.
• E) GP IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) paradoxically restore platelet function in Glanzmann thrombasthenia by occupying the vitronectin receptor (integrin alphav beta3) on platelets, which is upregulated to compensate for absent GP IIb/IIIa; blocking alphav beta3 reduces this compensatory aggregation and provides net antithrombotic benefit.

9. A 54-year-old woman with an NSTEMI (non-ST-elevation myocardial infarction) treated with drug-eluting stent placement is discharged on ticagrelor 90 mg twice daily, aspirin 81 mg, and atorvastatin. At a 3-week follow-up she reports episodic shortness of breath occurring at rest, with no exertion component, no chest pain, and no leg swelling. Her oxygen saturation is 98% on room air, her lungs are clear, her BNP (brain natriuretic peptide) is 42 pg/mL (normal), and her echocardiogram is unchanged from her pre-discharge study showing preserved EF (ejection fraction). A D-dimer is mildly elevated at 0.6 mg/L (laboratory upper limit 0.5). The cardiologist must decide whether to stop ticagrelor. Which of the following best describes the appropriate clinical interpretation and management of this presentation?

• A) The mildly elevated D-dimer in the context of new dyspnea mandates CT pulmonary angiography (CTPA) before any management decision about ticagrelor; ticagrelor should be held pending results because it cannot be continued if pulmonary embolism is confirmed, and P2Y12 inhibition must be transitioned to clopidogrel while anticoagulation is initiated.
• B) The dyspnea represents ticagrelor-induced bronchospasm requiring immediate discontinuation; substitution with clopidogrel is mandatory because ticagrelor's adenosine reuptake inhibition produces histamine-mediated bronchospasm that will worsen with continued exposure and has been associated with fatal respiratory events in post-marketing surveillance.
• C) The clinical picture — episodic rest dyspnea without exertional component, normal oxygen saturation, clear lungs, normal BNP, unchanged echocardiogram — is consistent with ticagrelor-associated dyspnea mediated by adenosine reuptake inhibition stimulating pulmonary vagal afferents; a mildly elevated D-dimer is expected post-MI and post-stent and does not require CTPA in this low-pretest-probability context; ticagrelor should be continued with patient reassurance, as this adverse effect does not require discontinuation in most patients and typically attenuates over time.
• D) The normal BNP and preserved EF exclude cardiac causes but the mildly elevated D-dimer with new dyspnea constitutes a high-probability Wells score for pulmonary embolism; ticagrelor must be stopped and replaced with rivaroxaban, which provides simultaneous anticoagulation and antiplatelet benefit through Factor Xa inhibition's secondary effects on PAR-1 signaling.
• E) Ticagrelor should be immediately switched to prasugrel because prasugrel does not inhibit adenosine reuptake and therefore does not cause dyspnea; this switch eliminates the adverse effect while maintaining potent P2Y12 inhibition with an irreversible thienopyridine during the high-risk early post-stent period.

10. A 62-year-old man who received ticagrelor 90 mg twice daily after ACS (acute coronary syndrome) has now completed 12 months of DAPT (dual antiplatelet therapy). His cardiologist plans to de-escalate his P2Y12 therapy to clopidogrel 75 mg daily for continued long-term secondary prevention, and asks the pharmacist to confirm the appropriate transition protocol. A second scenario involves a different patient on prasugrel 10 mg daily in the chronic maintenance phase being switched to clopidogrel. Which of the following correctly describes the expert consensus transition protocol for both switches and explains the pharmacological rationale for the timing differences?

• A) For both ticagrelor-to-clopidogrel and prasugrel-to-clopidogrel transitions, a 600 mg clopidogrel loading dose should be given simultaneously with the last dose of the current agent; simultaneous dosing ensures that clopidogrel bioactivation begins immediately and that there is no gap in P2Y12 inhibition as the prior agent's effect wanes.
• B) For ticagrelor-to-clopidogrel transition, no loading dose is required; clopidogrel 75 mg daily can be started the day after the last ticagrelor dose because ticagrelor's residual platelet inhibition covers the 3 to 5 days required for clopidogrel maintenance dosing to achieve steady-state platelet inhibition; for prasugrel-to-clopidogrel, a 300 mg load is given immediately when switching due to prasugrel's irreversible binding leaving a faster inhibition gap.
• C) For both transitions, the switch must be accomplished with a 7-day overlap period in which both agents are given concurrently; this overlap ensures continuous P2Y12 occupancy while clopidogrel's active metabolite accumulates to therapeutic levels; the 7-day overlap applies to both ticagrelor and prasugrel because both produce high-level P2Y12 receptor occupancy that must be gradually displaced by clopidogrel.
• D) For ticagrelor-to-clopidogrel transition, a 300 mg clopidogrel loading dose is given 48 hours after the last ticagrelor dose to allow complete ticagrelor clearance before initiating clopidogrel; giving clopidogrel while any ticagrelor remains in plasma risks pharmacokinetic competition at the CYP3A4 bioactivation step, reducing clopidogrel active metabolite generation.
• E) For ticagrelor-to-clopidogrel transition in the chronic maintenance phase (beyond 30 days post-ACS), a 600 mg clopidogrel loading dose is given 24 hours after the last ticagrelor dose to account for residual ticagrelor platelet inhibitory activity at 24 hours from reversible binding; for prasugrel-to-clopidogrel transition, a 600 mg clopidogrel loading dose is given immediately at the time of the switch, because prasugrel's irreversible binding means its per-platelet effect does not require ongoing plasma drug presence and the timing relative to clopidogrel initiation is less critical.

11. A 68-year-old man with persistent atrial fibrillation (AF) on apixaban undergoes PCI (percutaneous coronary intervention) with drug-eluting stent placement for an acute NSTEMI (non-ST-elevation myocardial infarction). After a brief period of triple therapy (apixaban plus clopidogrel plus aspirin), the care team debates which component to omit for long-term maintenance therapy. A fellow argues that the OAC (oral anticoagulant) should be replaced by DAPT (dual antiplatelet therapy) alone because the patient "just had a stent" and antiplatelet therapy is more relevant than anticoagulation in the first year. An attending challenges this reasoning. Which of the following most accurately applies the AUGUSTUS trial data to resolve this debate, and correctly identifies which antithrombotic component should be omitted?

• A) The fellow is correct: the AUGUSTUS trial demonstrated that OAC adds no benefit to DAPT in the AF-PCI (atrial fibrillation with recent PCI) population because the P2Y12 inhibitor provides sufficient atrial thrombus suppression through platelet activation pathways; aspirin and clopidogrel together provide equivalent stroke prevention to apixaban with less bleeding; OAC should be stopped at 30 days and DAPT continued alone for 12 months.
• B) The attending is correct: the AUGUSTUS trial demonstrated that omitting the OAC (replacing it with placebo) while continuing aspirin plus P2Y12 inhibitor did not prevent ischemic events but significantly increased ischemic stroke risk, confirming that OAC is irreplaceable for AF stroke prevention; the component that should be omitted is aspirin, which when added to OAC plus P2Y12 inhibitor doubled clinically relevant bleeding events without reducing the composite ischemic endpoint — making dual therapy (OAC plus P2Y12 inhibitor, without aspirin) the evidence-based default beyond the initial brief triple therapy period.
• C) The AUGUSTUS trial demonstrated that both the OAC and aspirin should be omitted after the initial 4-week triple therapy window; P2Y12 inhibitor monotherapy (clopidogrel alone) provides adequate combined stroke and stent thrombosis prevention in the maintenance phase of AF-PCI patients based on the PRoFESS and PLATO trials combined post-hoc analysis.
• D) The AUGUSTUS trial showed equivalent ischemic outcomes with and without aspirin but significantly less bleeding without aspirin; however, this benefit applied only to the warfarin arm of the trial — in the apixaban arm, aspirin did not significantly increase bleeding; therefore this patient on apixaban should continue triple therapy (apixaban plus clopidogrel plus aspirin) because the aspirin-omission benefit does not extend to DOAC-based regimens.
• E) The AUGUSTUS trial demonstrated that replacing OAC with high-dose aspirin (325 mg) provides equivalent stroke protection in AF-PCI patients because high-dose aspirin inhibits the platelet-fibrin thrombi responsible for AF-related stroke, while standard 81 mg aspirin does not; the fellow's recommendation to stop apixaban is therefore correct but only if the aspirin dose is escalated to 325 mg daily.

12. A 57-year-old man with a drug-eluting stent placed 3 weeks ago for STEMI (ST-elevation myocardial infarction) and currently on ticagrelor 90 mg twice daily requires urgent abdominal surgery for a perforated appendix. The surgical team accepts that some degree of P2Y12 inhibition will be necessary perioperatively given the very recent high-risk stent. The cardiologist recommends cangrelor IV as a perioperative bridging strategy. The surgical team asks how cangrelor would be managed around the time of incision and why it is uniquely suited for this role. Which of the following best describes the pharmacological basis for cangrelor's perioperative utility and the operative management protocol?

• A) Cangrelor is given as a 30 mcg/kg IV bolus followed by a 4 mcg/kg/min infusion; the infusion is continued through the surgical procedure and stopped at wound closure; its short plasma half-life means platelet function normalizes within 15 minutes of stopping, allowing safe hemostasis during closure; ticagrelor is restarted immediately at skin closure.
• B) Cangrelor should be started 24 hours before surgery to allow steady-state platelet inhibition to develop gradually; the infusion is stopped 6 hours before incision to allow partial platelet function recovery; this partial recovery provides a window of improved hemostasis while still maintaining enough P2Y12 inhibition to prevent stent thrombosis during and immediately after the procedure.
• C) Cangrelor cannot be used as a perioperative bridge because it is only approved for use during PCI procedures; its use in the perioperative bridging context is off-label and the BRIDGE trial, which evaluated cangrelor bridging, showed no benefit compared to placebo in reducing stent thrombosis; the appropriate strategy is to postpone surgery until the high-risk stent period has passed.
• D) Cangrelor's extremely short offset (platelet function returns to near-baseline within 60 to 90 minutes of stopping the infusion) makes it uniquely suited for perioperative bridging: the infusion can be maintained up to the time of surgery and stopped approximately 1 hour before incision, providing P2Y12 inhibition as close to the operative period as possible; post-operatively, when surgical hemostasis is established, oral P2Y12 therapy is restarted and cangrelor can be continued until the oral agent takes effect.
• E) Cangrelor bridging requires co-administration of a glycoprotein IIb/IIIa inhibitor throughout the perioperative period to ensure that platelet aggregation cannot occur through the GP IIb/IIIa-fibrinogen pathway during the brief offset window between cangrelor cessation and surgical incision; tirofiban is the preferred co-agent because of its rapid offset allowing it to also be stopped close to incision time.

13. A cardiologist is explaining to a fellow why platelet transfusion is more pharmacologically effective as a reversal strategy for abciximab-associated bleeding than for eptifibatide-associated bleeding, even though both agents inhibit the same receptor, GP IIb/IIIa. She asks the fellow to predict, based on each drug's binding mechanism, how transfused platelets would interact with residual drug in the circulation and what the net effect on platelet function would be. Which of the following correctly explains the differential efficacy of platelet transfusion as a reversal strategy for abciximab versus eptifibatide?

• A) For abciximab: transfused platelets provide a large pool of new, unoccupied GP IIb/IIIa receptors that bind and sequester abciximab molecules from plasma; because abciximab dissociates very slowly from any receptor it occupies, this redistribution from the original heavily loaded platelets to the transfused platelets effectively restores aggregation capacity of the entire platelet pool by diluting the per-platelet drug burden across a larger receptor pool; platelet transfusion is therefore a pharmacologically rational and effective reversal strategy. For eptifibatide: eptifibatide binds GP IIb/IIIa competitively and reversibly with a short plasma half-life; drug will dissociate from existing platelets on its own within 4 to 8 hours as plasma concentrations fall; transfused platelets will also become inhibited if plasma eptifibatide concentrations remain above the threshold for receptor occupancy, meaning that transfused platelets do not substantially accelerate recovery — drug elimination drives recovery for eptifibatide more than dilution of receptor load.
• B) Platelet transfusion is more effective for eptifibatide than for abciximab because eptifibatide's small cyclic peptide structure allows it to rapidly transfer between platelets; transfused platelets immediately redistribute eptifibatide away from endogenous platelets; abciximab's large Fab fragment transfers slowly between platelets, meaning transfused platelets cannot efficiently sequester abciximab from the existing platelet population.
• C) Platelet transfusion is equally effective for both agents because both agents produce reversible, non-covalent GP IIb/IIIa inhibition; adding unoccupied GP IIb/IIIa receptors through transfusion dilutes the total receptor occupancy for both drugs proportionally; the differential clinical efficacy reported in observational studies reflects differences in the underlying bleeding diathesis rather than pharmacological differences between the two agents.
• D) Platelet transfusion is ineffective for both agents because GP IIb/IIIa inhibitors occupy the receptor on transfused platelets as readily as on endogenous platelets; total circulating GP IIb/IIIa receptor number increases with transfusion but total drug load also distributes to transfused receptors, maintaining the same fractional receptor occupancy regardless of how many platelets are transfused.
• E) For eptifibatide, platelet transfusion is more effective than for abciximab because eptifibatide's renal elimination pathway is accelerated by the increase in renal blood flow that accompanies the volume expansion from platelet transfusion; the faster renal clearance of eptifibatide with transfusion restores platelet function more quickly than the slow redistribution mechanism that governs abciximab reversal.